R-Tech Ueno, Japanese pharmaceutical company, has filed for and received FDA IND approval to begin Phase I and II clinical trials of its severe dry eye treatment, RU -101.
Ophthalmic solution RU-101 contains the serum component albumin, which has shown to aid in the production of tears.
R-Tech Ueno hopes to gain marketing approval for the treatment soon.
More Articles on Ophthalmology:
Pharm, Olam, InSite Vision Complete Phase 3 Clinical Study
Study Finds 65% of Liver Transplant Patients Develop AMD
Glaucoma Management Lens to be Presented at ARVO 2013
Ophthalmic solution RU-101 contains the serum component albumin, which has shown to aid in the production of tears.
R-Tech Ueno hopes to gain marketing approval for the treatment soon.
More Articles on Ophthalmology:
Pharm, Olam, InSite Vision Complete Phase 3 Clinical Study
Study Finds 65% of Liver Transplant Patients Develop AMD
Glaucoma Management Lens to be Presented at ARVO 2013